Investor Presentation
22 June 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Investor Presentation
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that Executive Chairman Stephen West and proposed new Chief Executive Officer Ajan Reginald will provide a live presentation to discuss the Proposed Acquisition of Oncogeni and Proposed Placing via the Investor Meet Company platform on Friday, 24 June 2022 at 9am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:
https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
Investors who already follow ROQUEFORT THERAPEUTICSPLC on the Investor Meet Company platform will automatically be invited.
ENDS
Enquiries:
|
Roquefort Therapeutics plc |
|
|
Stephen West (Chairman) |
+44 (0)20 3290 9339
|
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
Optiva Securities Limited (Broker) |
+44 (0)20 7466 5000 |
|
Christian Dennis |
+44 (0)20 3411 1881 |
For further information on Roquefort Therapeutics, please visitwww.roquefortplc.comand @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company is a pre-clinical biotech company focused on developing first in class Midkine targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through publication in over 1,000 scientific journals, Roquefort Therapeutics has identified the p otential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Roquefort Therapeutics holds an exclusive licence to the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Roquefort Therapeutic's pre-clinical program is currently underway with an initial focus on cancer.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 6 minutes ago Associated British Foods
- 29 minutes ago Centaur Media
- 1 hour ago Wizz Air Holdings
- 1 hour ago Trifast
- 1 hour ago Molten Ventures